EVAX
Evaxion Biotech ASNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$37.49M
P/E Ratio
—
EPS
$-1.00
Beta
0.20
52W High
$12.15
52W Low
$1.42
50-Day MA
$3.83
200-Day MA
$4.29
Dividend Yield
—
Profit Margin
-102.40%
Forward P/E
3.57
PEG Ratio
—
About Evaxion Biotech AS
Evaxion Biotech A / S, a clinical-stage artificial intelligence and immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company is headquartered in Hoersholm, Denmark.
Fundamentals
| Revenue (TTM) | $7.53M |
| Gross Profit (TTM) | $7.53M |
| EBITDA | $-8.87M |
| Operating Margin | -122.70% |
| Return on Equity | -100.20% |
| Return on Assets | -28.20% |
| Revenue/Share (TTM) | $1.18 |
| Book Value | $2.04 |
| Price-to-Book | 2.20 |
| Price-to-Sales (TTM) | 4.98 |
| EV/Revenue | 2.89 |
| EV/EBITDA | -0.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $8.34M |
| Float | $283.97M |
| % Insiders | 17.47% |
| % Institutions | 7.28% |
Historical Volatility
HV 10-Day
63.31%
HV 20-Day
53.81%
HV 30-Day
57.41%
HV 60-Day
79.50%
HV Rank
4.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($11.25 target)
1
Strong Buy3
BuyData last updated: 5/2/2026